

Evaluating the Dose, Safety, Tolerability, and Immunogenicity of Mosaic Hexavalent Influenza Vaccine VRCFLUMOS0116-00-VP (Flu-Mos-v2) With and Without ALFQ Adjuvant in Healthy Adults

NCT06863142

Status	RECRUITING
Phase	Phase 1
Sponsor	National Institute of Allergy and Infectious Diseases (NIAID)
Enrollment	45 participants

Key Eligibility Criteria

Inclusion (2)

- A participant must meet all of the following criteria:
- Healthy adults between the ages of 18-50 years, inclusive

Exclusion (52)

- Received at least one licensed influenza vaccine from the 2020-2021 influenza season through the 2024-2025 influenza season
- Able and willing to complete the informed consent process
- Available for clinic visits for 68 weeks after enrollment, including through the 2025-2026 influenza season
- Able to provide proof of identity to the satisfaction of the study clinician completing the enrollment process
- Physical examination and laboratory results without clinically significant findings and a Body Mass Index (BMI) ≤ 35 within the 56 days before enrollment
- ... and 47 more (see full listing online)

Locations (1 total)

National Institutes of Health Clinical Center, Bethesda, Maryland, United States